

**RECEIVED
CENTRAL FAX CENTER**

APR 06 2006

Please type a plus sign (+) inside this box → +

PTO/SB/21 (08-00)

Approved for use through 10/31/2002, OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission **4**

Application Number **10/017,718**

Filing Date **December 14, 2001**

First Named Inventor **WEISGRABER, KARL H.**

Group Art Unit **1632**

Examiner Name **T.N. Ton**

Attorney Docket Number **UCAL-222**

ENCLOSURES (check all that apply)

- Fee Transmittal Form
 - Fee Attached
- Amendment / Reply
 - After Final
 - Affidavits/declaration(s)
- Extension of Time Request
- Express Abandonment Request
- Information Disclosure Statement
- Certified Copy of Priority Documents
- Response to Missing Parts/ Incomplete Application
- Response to Missing Parts under 37 CFR 1.52 or 1.53

- Assignment Papers (for an Application)
 - Drawing(s)
- Licensing-related Papers
- Petition
- Petition to Convert to a Provisional Application
- Power of Attorney, Revocation
- Change of Correspondence Address
- Terminal Disclaimer
- Request for Refund
- CD. Number of CD(s)

- After Allowance Communication to Group
- Appeal Communication to Board of Appeals and Interferences
- Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- Proprietary Information
- Status Letter
- Other Enclosure(s) (please identify below):
 - 1) Communication (1 pg.)
 - 2) Declaration (2 pgs.)

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name

PAULA A. BORDEN, Reg. No. 42,344

Signature

April 6, 2006

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile filed under 37 C.F.R. §§ 1.6(d) and 1.8(a)(1)(b) addressed to: 571-273-0736 on this date: April 6, 2006.

Typed or printed name **Cindy Kim Hoang**

Signature 

Date **April 6, 2006**

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: P.O. Box 1450 Alexandria VA 22313-1450.

Facsimile No. 571-273-0736

RECEIVED
CENTRAL FAX CENTER
APR 06 2006

COMMUNICATION	Attorney Docket Confirmation No.	UCAL-222 5282
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	First Named Inventor	K.H. Weisgraber
	Application Number	10/017,718
	Filing Date	December 14, 2001
	Group Art Unit	1632
	Examiner Name	T.N. Ton
	Title	<i>Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof</i>

Sir:


Applicants submit herewith a Declaration under 37 C.F.R. §1.132. On April 4, 2006, Examiner Ton called the undersigned, and indicated that the Declaration under 37 C.F.R. §1.132 as filed in this application on February 1, 2006, should be amended to include a statement that the amendatory material includes no new matter.

The Declaration under 37 C.F.R. §1.132 submitted herewith includes a statement that the amendatory material includes no new matter.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number UCAL-222.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

By:


 Paula A. Borden
 Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
 1900 University Avenue, Suite 200
 East Palo Alto, CA 94303
 Telephone: (650) 327-3400
 Facsimile: (650) 327-3231

Atty Dkt. No.: UCAL-222
 USSN: 10/017,718
 Exhibit 1

FACSIMILE NO. 571-273-0733		RECEIVED CENTRAL FAX CENTER APR 06 2006
<p>DECLARATION UNDER 37 C.F.R. § 1.132 AND 37 C.F.R. §1.57 (f)</p> <p>Address to: Commissioner for Patents Alexandria, VA 22313-1450</p>	Attorney Docket Confirmation No.	UCAL-222 5282
	First Named Inventor	K.H. Weisgraber
	Application Number	10/017,718
	Filing Date	December 14, 2001
	Group Art Unit	1632
	Examiner Name	T.N. Ton
	Title	Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof

Dear Sir:

1. I, Paula A. Borden, declare and say I am agent of record in the above-captioned patent application.


2. An amendment, filed on July 6, 2004 in this application, amended the specification and drawings to include the following amendatory material: 1) new Figures 5A and 5B; and 2) a new paragraph on page 17, between paragraphs 0068 and 0069. The amendatory material was added to include material incorporated by reference in the specification. Specifically, paragraph 0068 of the instant specification refers to Weisgraber ((1994) *Adv. Protein Chem.* 45:249-302; "Weisgraber") for the disclosure of amino acid sequences of apoE from a variety of species. New Figures 5A and 5B correspond to Figure 1 on page 252 of Weisgraber, which Figure 1 provides amino acid sequences of apoE from a variety of species; and the new paragraph corresponds to the legend to Figure 1 of Weisgraber. The April 20, 2004 Office Action requested that the disclosure be amended to include the material incorporated by reference to Weisgraber.

Atty Dkt. No.: UCAL-222
USSN: 10/017,718
Exhibit 1

3. As provided for in MPEP §608.01(p) and 37 C.F.R. §1.57(f), I declare that the amendatory material consists of the same material incorporated by reference in this application; and that the amendatory material adds no new matter.

4. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title XVIII of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Apr. 6, 2006
Date



Paula A. Borden